Unrolled primal-dual networks for lensless cameras

Conventional models for lensless imaging assume that each measurement results from convolving a given scene with a single experimentally measured point-spread function. These models fail to simulate lensless cameras truthfully, as these models do not account for optical aberrations or scenes with depth variations. Our work shows that learning a supervised primal-dual reconstruction method results in image quality matching state of the art in the literature without demanding a large network capacity. We show that embedding learnable forward and adjoint models improves the reconstruction quality of lensless images (+5dB PSNR) compared to works that assume a fixed point-spread function

Optimizing vision and visuals: lectures on cameras, displays and perception

The evolution of the internet is underway, where immersive virtual 3D environments (commonly known as metaverse or telelife) will replace flat 2D interfaces. Crucial ingredients in this transformation are next-generation displays and cameras representing genuinely 3D visuals while meeting the human visual system's perceptual requirements. This course will provide a fast-paced introduction to optimization methods for next-generation interfaces geared towards immersive virtual 3D environments. Firstly, we will introduce lensless cameras for high dimensional compressive sensing (e.g., single exposure capture to a video or one-shot 3D). Our audience will learn to process images from a lensless camera at the end. Secondly, we introduce holographic displays as a potential candidate for next-generation displays. By the end of this course, you will learn to create your 3D images that can be viewed using a standard holographic display. Lastly, we will introduce perceptual guidance that could be an integral part of the optimization routines of displays and cameras. Our audience will gather experience in integrating perception to display and camera optimizations. This course targets a wide range of audiences, from domain experts to newcomers. To do so, examples from this course will be based on our in-house toolkit to be replicable for future use. The course material will provide example codes and a broad survey with crucial information on cameras, displays and perception

Breaking the Bluetooth Pairing – The Fixed Coordinate Invalid Curve Attack

Bluetooth is a widely deployed standard for wireless communications between mobile devices. It uses authenticated Elliptic Curve Diffie-Hellman for its key exchange. In this paper we show that the authentication provided by the Bluetooth pairing protocols is insufficient and does not provide the promised MitM protection. We present a new attack that modifies the y-coordinates of the public keys (while preserving the x-coordinates). The attack compromises the encryption keys of all of the current Bluetooth authenticated pairing protocols, provided both paired devices are vulnerable. Specifically, it successfully compromises the encryption keys of 50% of the Bluetooth pairing attempts, while in the other 50% the pairing of the victims is terminated. The affected vendors have been informed and patched their products accordingly, and the Bluetooth specification had been modified to address the new attack. We named our new attack the “Fixed Coordinate Invalid Curve Attack”. Unlike the well known “Invalid Curve Attack” of Biehl et. al. which recovers the private key by sending multiple specially crafted points to the victim, our attack is a MitM attack which modifies the public keys in a way that lets the attacker deduce the shared secret

Comparative performance of the InBios SCoV-2 Detect TM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations

The InBios SCoV-2 Detect™ IgG ELISA (InBios) and the in-house KWTRP ELISA (KWTRP) have both been used in the estimation of SARS-CoV-2 seroprevalence in Kenya. Whereas the latter has been validated extensively using local samples, the former has not. Such validation is important for informing the comparability of data across the sites and populations where seroprevalence has been reported. We compared the assays directly using pre-pandemic serum/plasma collected in 2018 from 454 blood donors and 173 malaria cross-sectional survey participants, designated gold standard negatives. As gold standard SARS-CoV-2 positive samples: we assayed serum/plasma from 159 SARS-CoV-2 PCR-positive patients and 166 vaccination-confirmed participants. The overall agreement on correctly classified samples was >0.87 for both assays. The overall specificity was 0.89 (95% CI, 0.87-0.91) for InBios and 0.99 (95% CI, 0.97-0.99) for KWTRP among the gold standard negative samples while the overall sensitivity was 0.97 (95% CI, 0.94-0.98) and 0.93 (95% CI, 0.90- 0.95) for InBios and KWTRP ELISAs respectively, among the gold standard positive samples. In all, the positive predictive value for InBios was 0.83 (95% CI, 0.79-0.87) and 0.98 (95% CI, 0.96-0.99) for KWTRP while the negative predictive value was 0.98 (95% CI, 0.97- 0.99) and 0.97 (95% CI, 0.95-0.98) for InBios and KWTRP respectively. Overall, both assays showed sufficient sensitivity and specificity to estimate SARS-CoV-2 antibodies in different populations in Kenya

Taming the many EdDSAs

This paper analyses security of concrete instantiations of EdDSA by identifying exploitable inconsistencies between standardization recommendations and Ed25519 implementations. We mainly focus on current ambiguity regarding signature verification equations, binding and malleability guarantees, and incompatibilities between randomized batch and single verification. We give a formulation of Ed25519 signature scheme that achieves the highest level of security, explaining how each step of the algorithm links with the formal security properties. We develop optimizations to allow for more efficient secure implementations. Finally, we designed a set of edge-case test-vectors and run them by some of the most popular Ed25519 libraries. The results allowed to understand the security level of those implementations and showed that most libraries do not comply with the latest standardization recommendations. The methodology allows to test compatibility of different Ed25519 implementations which is of practical importance for consensus-driven applications

Achievement of target gain larger than unity in an inertial fusion experiment.

On December 5, 2022, an indirect drive fusion implosion on the National Ignition Facility (NIF) achieved a target gain G_{target} of 1.5. This is the first laboratory demonstration of exceeding "scientific breakeven" (or G_{target}>1) where 2.05 MJ of 351 nm laser light produced 3.1 MJ of total fusion yield, a result which significantly exceeds the Lawson criterion for fusion ignition as reported in a previous NIF implosion [H. Abu-Shawareb et al. (Indirect Drive ICF Collaboration), Phys. Rev. Lett. 129, 075001 (2022)PRLTAO0031-900710.1103/PhysRevLett.129.075001]. This achievement is the culmination of more than five decades of research and gives proof that laboratory fusion, based on fundamental physics principles, is possible. This Letter reports on the target, laser, design, and experimental advancements that led to this result

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort

Objectives:We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged-infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies.Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries.Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DALI study, 182 met inclusion criteria. Overall, 89.0% (162/182) of patients achieved the most conservative target of 50% fT(> MIC) (time over which unbound or free drug concentration remains above the MIC). Decreasing creatinine clearance and the use of prolonged infusion significantly increased the PTA for most pharmacokinetic/pharmacodynamic targets. In the subgroup of patients who had respiratory infection, patients receiving beta-lactams via prolonged infusion demonstrated significantly better 30 day survival when compared with intermittent-bolus patients [86.2% (25/29) versus 56.7% (17/30); P=0.012]. Additionally, in patients with a SOFA score of >= 9, administration by prolonged infusion compared with intermittent-bolus dosing demonstrated significantly better clinical cure [73.3% (11/15) versus 35.0% (7/20); P=0.035] and survival rates [73.3% (11/15) versus 25.0% (5/20); P=0.025].Conclusions: Analysis of this large dataset has provided additional data on the niche benefits of administration of piperacillin/tazobactam and meropenem by prolonged infusion in critically ill patients, particularly for patients with respiratory infections

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.

Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and October 2024 using sera from representative samples of the Kenyan population. From our genomics data, we identified the most prevalent Kenyan and global variants and performed pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show that antibodies from individuals in the general population in Kenya were less effective against the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1) compared to the ancestral wildtype strain. Although there was increased neutralization following multiple doses of vaccine, antibodies from > 40% of the vaccinated individuals did not neutralize the omicron variants, suggesting that individuals were susceptible to infection by these variants